Structure Therapeutics starts the ACCOMPLISH Phase 3 program for aleniglipron

Structure Therapeutics has started enrolling patients in ACCOMPLISH-1 and ACCOMPLISH-2, the two pivotal Phase 3 obesity trials for its experimental oral GLP-1 drug aleniglipron. The two studies were posted to the US government trial registry within days of each other and are listed under identifiers NCT07654361 and NCT07654374 ^[1][2]. Topline results are expected in the second half of 2028.

ACCOMPLISH-1 is the larger of the two, with a target enrollment of about 3,600 participants ^[1]. ACCOMPLISH-2 is targeting roughly 1,100 participants ^[2]. Together, the program is designed to generate the efficacy and safety database that a drugmaker needs before it can ask the Food and Drug Administration to approve a new weight-loss medicine.

Aleniglipron is a small-molecule GLP-1 receptor agonist taken by mouth, not an injection. That puts it in the same category as orforglipron, the Eli Lilly pill sold under the brand name Foundayo. Both differ from semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound), which are peptide drugs. Rybelsus is an oral form of semaglutide but is a peptide and carries food and water timing rules; small-molecule pills are being developed partly to avoid those constraints. Aleniglipron is widely viewed as the closest biotech-developed challenger to orforglipron, though it is several years behind in development.

What the trial records do and do not show

The registry entries confirm the trials exist and are recruiting, along with their identifiers and enrollment targets ^[1][2]. Beyond that, the material available here does not spell out the full study design — including the doses being tested, whether there is an active comparator or only placebo, how long participants stay on treatment, the primary endpoint definition, or the list of participating sites. Those details are not yet confirmed in the sources reviewed for this story, and readers should treat any specific numbers about expected weight loss as unknown until results are reported.

Also not established in these sources: how aleniglipron's side effect profile compares with approved GLP-1 drugs, whether the program includes people with type 2 diabetes as well as obesity, and whether any cardiovascular outcomes study is planned.

Why it matters for patients

The practical significance is timing and supply. Injectable GLP-1 medicines have faced shortages, high list prices, and insurance hurdles in the United States. Pills that can be made through standard chemical manufacturing, rather than peptide synthesis, are generally easier and cheaper to scale, which is the main argument for why more oral options could eventually ease those pressures. But that argument is about manufacturing, not about whether any individual drug works better.

For someone weighing options today, the start of Phase 3 changes nothing about what is available at the pharmacy. Aleniglipron is investigational. It has not been approved by the FDA for any use, and no approval is possible before the pivotal data arrive. With topline results expected in the second half of 2028, an FDA filing and review would follow after that, meaning commercial availability — if the drug succeeds — would be years away.

The other reason this matters is competition. A second or third oral GLP-1 reaching the market would give prescribers more choices and could affect pricing. Whether aleniglipron gets there depends on results that do not yet exist.

What happens next

• Now through 2027: Enrollment continues for ACCOMPLISH-1 and ACCOMPLISH-2 ^[1][2]. People interested in participating can look up the trial identifiers in the federal registry for site and eligibility information.
• Second half of 2028: Topline results expected.
• After that: Any regulatory submission, review timeline, or launch date is not yet known.